Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALE Teens: Liraglutide for Adolescent Obesity
NCT02918279Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Liraglutide Arm with Placebo Arm (2 arms). Primary endpoint: Change in Body Mass Index Standard Deviation Score at 56 weeks. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02918279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918279.